Hepatitis B surface antigen clearance in inactive hepatitis B surface antigen carriers treated with peginterferon alfa-2a

doi:10.4254/wjh.v8.i15.637

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 8, Issue 15

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (8017)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-1) series.

Item

Count

PDF

657

WORD

351

HTML

3225

Figures (1-1)

195

Tables (1-1)

207

Sum=4635

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

356

Download

715

Sum=1071

Publishing Process of This Article

Item

Count

Browse

920

Download

1391

Sum=2311

May 28, 2016 (publication date) through Jun 2, 2024

Times Cited of This Article

Times Cited (21)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Cohort Study

World J Hepatol. May 28, 2016; 8(15): 637-643
Published online May 28, 2016. doi: 10.4254/wjh.v8.i15.637

Open in New Tab Full Size Figure Download Figure

Figure 1 Mean hepatitis B surface antigen level decreased in a time-dependent manner in treated patients and was significantly lower at week 24 than at baseline. HBsAg: Hepatitis B surface antigen.

Citation: Li MH, Xie Y, Zhang L, Lu Y, Shen G, Wu SL, Chang M, Mu CQ, Hu LP, Hua WH, Song SJ, Zhang SF, Cheng J, Xu DZ. Hepatitis B surface antigen clearance in inactive hepatitis B surface antigen carriers treated with peginterferon alfa-2a. World J Hepatol 2016; 8(15): 637-643
URL: https://www.wjgnet.com/1948-5182/full/v8/i15/637.htm
DOI: https://dx.doi.org/10.4254/wjh.v8.i15.637